Cantor Fitzgerald Reiterates Overweight on Novo Nordisk, Maintains $160 Price Target

Moomoo 24/7 ·  Apr 18 09:59

Cantor Fitzgerald analyst Louise Chen reiterates Novo Nordisk (NYSE:NVO) with a Overweight and maintains $160 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment